“The scale of the clinical changes spurred by amyloid PET imaging were twice as great as we had anticipated,” Rabinovici told Healio Psychiatry. “Based on the current findings, the expanded availability of these tests would have a major impact on patients by ensuring they get the right diagnosis, the right medications and have the opportunity to enroll in relevant clinical trials.”
-Gil D. Rabinovici, MD
Amyloid PET changed the clinical management in most patients with mild cognitive impairment and most patients with dementia, according to study findings. Future Diagnostics Group is honored and privileged to have been a top participant for the IDEAS study; the nationwide Medicare sponsored study from 2016-2018. Click Here for more information on the findings.
For an Amyloid PET scan please call (815)73003344 ext. 125